| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1376650 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Abstract
The efficient and short synthetic route to the structurally novel bimodal ligand NETA for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer was developed. The structure of NETA was determined by X-ray crystallography. The arsenazo-based UV spectroscopic complexation kinetics data suggest that NETA is a promising chelator for use in RIT applications of 212Bi, 213Bi, and 177Lu.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Hyun-Soon Chong, Hyun A. Song, Noah Birch, Thien Le, Sooyoun Lim, Xiang Ma,